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Abstract 
Interleukin-29 (IL-29) is a cytokine belonging to the type III interferon family. It was recently 
detected in the gingival crevicular fluid of periodontitis patients. However, the role of IL-29 
in the pathogenesis of periodontal disease remains unknown. The aim of this study was to 
examine the effects of IL-29 on C-X-C motif chemokine ligand 10 (CXCL10) production in 
human oral epithelial cells. We measured CXCL10 production in TR146 cells, which is a 
human oral epithelial cell line, using an enzyme-linked immunosorbent assay. We used 
Western blot analysis to detect IL-29 receptor expression and the phosphorylation levels of 
signal transduction molecules, including p38 mitogen-activated protein kinases (MAPK), 
signal transducer and activator of transcription 3 (STAT3), and nuclear factor (NF)-κB p65, 
in the TR146 cells. The TR146 cells expressed the IL-29 receptor. IL-29 induced CXCL10 
production in the TR146 cells. IL-29 significantly enhanced CXCL10 production in tumor 
necrosis factor (TNF)-α-stimulated TR146 cells. The p38 MAPK, STAT3, and NF-κB 
pathways were found to be related to the IL-29-induced enhancement of CXCL10 production 
in TNF-α-stimulated TR146 cells. IL-29 promotes T helper 1 cell accumulation in 
periodontal lesions by inducing CXCL10 production in oral epithelial cells. 
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Introduction  
Interleukin-29 (IL-29) is a newly discovered cytokine belonging to the type III interferon 
family [Witte et al., 2010]. Recently, it was reported that IL-29 is involved in the 
pathogenesis of some diseases including Hashimoto's thyroiditis [Arpaci et al., 2016]. IL-29 
is mainly produced by leukocytes, such as dendritic cells [Wolk et al., 2008]. In addition, it 
was reported that stimulation with IL-4 [Megjugorac et al., 2010] or herpes simplex virus 
[Melchjorsen et al., 2006] induced IL-29 production in dendritic cells. IL-29 has antiviral and 
immunomodulatory properties [Li et al., 2009], and IL-29 knockout mice exhibited increased 
susceptibility to respiratory virus infections, including influenza virus [Qian et al., 2013]. 
IL-29 was found to decrease the production of T helper 2 (Th2)-type cytokines, including 
IL-4, IL-5, and IL-13, in some types of cells [Srinivas et al., 2008; Li et al., 2014]. Recently, 
Shivaprasad and Pradeep reported that patients with chronic/aggressive periodontaitis display 
higher gingival crevicular fluid IL-29 levels than healthy donors [Shivaprasad et al., 2013]. 
So, we hypothesized that IL-29 might modulate immune responses in periodontal lesions. 
It is known that immune responses in periodontal lesions play an important role in the 
progression of periodontal disease, and cytokines produced by leukocytes are involved in 
bone resorption in periodontal lesisons [Souza et al., 2008]. In particular, T-cell phenotypes 
affect susceptibility to periodontitis, as well as the initiation and severity of the condition 
[Gaffen et al., 2008]. Chen et al. recently reported that the levels of interferon (IFN)-γ were 
higher in periodontal lesions than in healthy donors [Chen et al., 2016]. Rajesh et al. also 
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demonstrated that the expression of T-bet, which is a Th1-cell transcription factor, was 
elevated in patients with periodontal disease [Rajesh et al., 2015]. These results showed that 
the number of Th1 cells was increased in periodontal lesions and that Th1 cells are involved 
in the pathogenesis of periodontitis. So, it is important to examine the mechanism responsible 
for Th1-cell accumulation in tissues affected by periodontal disease.  
CXC chemokine ligand (CXCL) 10 is a chemokine that plays a crucial role in Th1-cell 
accumulation in periodontal lesions [Taubman et al., 2001]. We previously reported that 
periodontal resident cells produce CXCL10. Tumor necrosis factor (TNF)-α, IFN-γ, 
oncostatin M, and IL-1β can induce CXCL10 production in human gingival fibroblasts and 
human periodontal ligament cells [Hosokawa et al., 2009; Hosokawa et al., 2010; Hosokawa 
et al., 2015]. However, it is unclear if IL-29 has the ability to induce CXCL10 production in 
periodontal tissue. 
The aim of this study was to investigate the effects of IL-29 on CXCL10 production in oral 
epithelial cells. Moreover, we examined which intracellular signal transduction pathways are 
involved in CXCL10 production in IL-29-stimulated human oral epithelial cells. 
Materials and Methods 
Cell culture 
The human oral epithelial cell line TR146, which was isolated from a human buccal 
carcinoma, was kindly provided by Dr Mark Herzberg (University of Minnesota, MN, USA). 
It is reported that TR146 cells show some morphological similarities to the human buccal 
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epithelial cells [Jacobsen et al., 1999] TR146 cells were used as human oral epithelial cell 
line in some previous papers [Hiroshima et al., 2016; Kohli et al., 2014; Sorenson et al., 
2012]. TR146 cells were grown in Ham’s F12 medium (Nacalai Tesque, Kyoto, Japan) 
supplemented with 10% fetal bovine serum (JRH Biosciences, Lenexa, KS, USA), 1 mmol/L 
sodium pyruvate (Gibco, Grand Island, MI, USA), and antibiotics (penicillin G, 100 units/ml; 
streptomycin, 100 µg/ml; Gibco) at 37OC in humidified air with 5% CO2. When the cells 
reached subconfluence, they were harvested and subcultured. 
CXCL10 production in TR146 cells 
TR146 cells were stimulated with recombinant human IL-29 (1, 10, or 100 ng/ml; Peprotech, 
Rocky Hill, NJ, USA) with or without TNF-α (10 ng/ml: Peprotech) for 24 hours. The 
supernatants of the TR146 cells were collected, and their CXCL10 concentrations were 
measured in triplicate using enzyme-linked immunosorbent assays (ELISA). Duoset ELISA 
kits (R&D Systems, Minneapolis, MN, USA) were used to obtain these measurements. All 
assays were performed according to the manufacturer’s instructions, and the CXCL10 level 
was determined using the standard curve prepared for each assay. In selected experiments, the 
TR146 cells were cultured for 1 hour in the presence or absence of SB203580 (10 µM; Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), PD98059 (10 µM; Santa Cruz Biotechnology), 
SP600125 (10 µM; Santa Cruz Biotechnology), fludarabine (50 µM; Cayman Chemical, Ann 
Arbor, MI, USA), WP1066 (5 µM; Santa Cruz Biotechnology), 10-DEBC hydrochloride (5 
µM; Santa Cruz Biotechnology), or SC514 (10 µM; Santa Cruz Biotechnology), prior to the 
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incubation of the cells with IL-29. 
Western blot analysis 
Western blot analysis was performed to detect IL-29 receptor expression and the IL-29 with 
or without TNF-α-induced phosphorylation of signal transduction molecules. TR146 cells 
were stimulated with IL-29 (100 ng/ml) or TNF-α (10 ng/ml) for 15, 30, or 60 minutes; 
washed once with cold phosphate-buffered saline; and then incubated on ice for 10 min with 
cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA) supplemented with 
protease inhibitor cocktail (Sigma–Aldrich, St. Louis, MO, USA). After removing any debris 
via centrifugation, the protein concentrations of the lysates were quantified with the Bradford 
protein assay using IgG as a standard. Twenty-µg protein samples were loaded onto 4-20% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel, before being 
electrotransferred to polyvinylidene difluoride membranes. The membranes were then 
blocked with 1% non-fat dried milk for 1 hour and reacted with the anti-human IL-10 
receptor β mouse monoclonal antibody (R&D Systems, catalog number MAB874, 1 μg/ml), 
anti-human IL-28 receptor α mouse monoclonal antibody (BioLegend, San Diego, CA, 
catalog number 337802, 1 μg/ml), anti-phospho-p38 MAPK rabbit monoclonal antibody 
(Cell Signaling Technology, catalog number 8632, 1000 times dilution), 
anti-phospho-STAT3 rabbit monoclonal antibody (Cell Signaling Technology, catalog 
number 9145, 2000 times dilution), anti-phospho-NF-κB p65 rabbit monoclonal antibody 
(Cell Signaling Technology, catalog number 3033, 1000 times dilution), anti-p38 MAPK 
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rabbit monoclonal antibody (Cell Signaling Technology, catalog number 8690, 1000 times 
dilution), anti-STAT3 mouse monoclonal antibody (Cell Signaling Technology, catalog 
number 9139, 2000 times dilution), anti-NF-κB p65 rabbit monoclonal antibody (Cell 
Signaling Technology, catalog number 8242, 1000 times dilution), or anti-GAPDH rabbit 
monoclonal antibody (Cell Signaling Technology, catalog number 5174, 6000 times dilution) 
overnight. The membranes were incubated with the horseradish peroxidase-conjugated 
secondary antibody (Sigma) for 1 hour at room temperature, and then detection was 
performed using the ECL prime Western blotting detection system (GE Healthcare, Uppsala, 
Sweden). The quantitation of the chemiluminescent signals was carried out using ImageJ 
(version 1.44). 
Statistical analysis 
Statistical significance was analyzed using the Student’s t test. P-values of <0.05 were 
considered to be significant. 
Results 
IL-29 receptor expression in TR146 cells 
It is reported that both IL-10 receptor β and IL-28 receptor α are required to recognize IL-29 
[Sheppard et al., 2003]. Therefore, we examined the expression of IL-10 receptor β, and 
IL-28 receptor α in TR146 cells. Fig. 1 shows that both IL-10 receptor β and IL-28 receptor 
α are expressed in TR146 cells.  
The effect of IL-29 on CXCL10 production in TR146 cells 
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Th1 cells are involved in the pathogenesis of periodontal disease [Taubman et al., 2001]. So, 
it is important to examine CXCL10 production because CXCL10 is a key chemokine for 
Th1-cell accumulation in inflammatory lesions. We examined whether IL-29 was able to 
induce CXCL10 production in TR146 cells. Fig. 2 shows that IL-29 enhanced CXCL10 
production in TR146 cells in a concentration-dependent manner. 
The effect of IL-29 on CXCL10 production in TNF-α-stimulated TR146 cells 
It is known that TNF-α is able to induce CXCL10 production in epithelial cells [Wu et al., 
2015]. Therefore, we hypothesized that IL-29 might modulate the CXCL10 production 
induced by TNF-α in TR146 cells. Fig. 3 shows that TNF-α (10 ng/ml) induced CXCL10 
production (245.12±6.33 pg/ml) and IL-29 (100 ng/ml) enhanced CXCL10 production in 
TNF-α-stimulated TR146 cells (1633.9±255.65 pg/ml, p=0.0101).  
Effects of signal transduction inhibitors on CXCL10 production in IL-29-stimulated 
TR146 cells 
Next, we examined which signal transduction pathways are involved in CXCL10 production 
in IL-29-treated TR146 cells using chemical inhibitors. We focused on the MAPK, STAT, Akt, 
and NF-κB pathways because it is known that CXCL10 production is modulated by these 
pathways [Sauty et al., 1999]. IL-29 (100 ng/ml) could induce CXCL10 production (926.95 
±37.78 pg/ml). SB203580 (a p38 MAPK inhibitor), WP1066 (a STAT3 inhibitor), and 
SC514 (an NF-κB inhibitor) suppressed CXCL10 production (560.79 ±24.59 pg/ml 
p=0.0019, 562.63 ±31.87 pg/ml p=0.00026, 400.13 ±81.08 pg/ml p=0.0056, respectively ). 
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On the other hand, PD98059 (an extracellular signal-regulated kinase [ERK] inhibitor), 
SP600125 (a c-Jun N-terminal kinase [JNK] inhibitor), and 10-DEBC hydrochloride (an Akt 
inhibitor) increased CXCL10 production (1453.34 ±22.95 pg/ml p=0.00035, 1899.61 ±
88.01 pg/ml p=0.0017, 1455.69 ±156.23 pg/ml p=0.015, respectively). Fludarabine (STAT1 
inhibitor) did not modulate CXCL10 production (918.67 ±21.81 pg/ml p=0.075). These 
findings indicate that the p38 MAPK, STAT3, and NF-κB pathways have positive effects on 
CXCL10 production, and the ERK, JNK, and Akt pathways negatively modulate CXCL10 
production in IL-29-stimulated TR146 cells.  
The effects of IL-29 on p38 MAPK, STAT3, and NF-κB p65 phosphorylation in 
TNF-α-stimulated TR146 cells 
Fig. 4 shows that the p38 MAPK, STAT3, and NF-κB pathways have positive effects on 
CXCL10 production in TR146 cells. Therefore, we examined the levels of p38 MAPK, 
STAT3, and NF-κB phosphorylation in TNF-α/IL-29-stimulated TR146 cells and compared 
them with those seen in IL-29-stimulated TR146 cells to elucidate which signal pathways are 
involved in the enhancement of CXCL10 production. Fig. 5 clearly shows that the 
TNF-α/IL-29-stimulated TR146 cells exhibited greater p38 MAPK, STAT3, and NF-κB 
phosphorylation levels than the IL-29-stimulated TR146 cells. 
Discussion 
In this study, we showed that IL-29 induced CXCL10 production in human oral epithelial 
cells. This is the first study to demonstrate that IL-29 has the ability to induce Th1-type 
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chemokine production in periodontal resident cells. Witte et al. recently reported that IL-29 
induced CXCL9, CXCL10, and CXCL11 production in human keratinocytes [Witte et al., 
2016]. We examined CXCL9 and CXCL11 production in TR146 cells using ELISA. However, 
we could not detect either of these molecules. They also stated that IL-29 induced the 
production of much smaller amounts of CXCL9 in human keratinocytes. Therefore, it is 
possible that IL-29 induces the production of small amounts of CXCL9 and CXCL11 in 
TR146 cells. However, these chemokines might have almost no effect on Th1-cell 
accumulation in periodontal lesions. Pekarek et al. detected IL-29 increased mRNA levels of 
CXCL9, CXCL10, and CXCL11 in peripheral blood mononuclear cells [Pekarek et al., 2007], 
and leukocytes are known to be are present in periodontal lesions. So, IL-29 might induce 
CXCL10 production in epithelial cells and leukocytes and increase the number of Th1 cells 
in periodontal lesions. However, the amounts of CXCL9, CXCL10, and CXCL11 in 
IL-29-induced human leukocytes are unknown, and it is also uncertain which types of 
leukocytes contribute to CXCL9, CXCL10, and CXCL11 production. We should examine the 
effects of IL-29 on leukocytes to address these questions.  
We clearly showed that IL-29 (100 ng/ml) synergistically increased CXCL10 production in 
TNF-α (10 ng/ml)-stimulated TR146 cells. This is the first study to find that IL-29 enhances 
TNF-α-induced inflammatory mediator expression. On the other hand, other studies have 
demonstrated that IL-29 is able to modulate the cytokine expression induced by other 
molecules. For example, Xu et al. reported that IL-29 increased IL-6 and IL-8 production in 
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peptidoglycan, polycytidylic acid, or lipopolysaccharide-stimulated human synovial 
fibroblasts [Xu et al., 2013]. They also reported that IL-29 (100 ng/ml) enhanced IL-6, IL-8, 
and TNF-α (10 ng/ml) production in lipopolysaccharide-stimulated RAW264.7 cells [Xu et 
al., 2015]. These reports and our results indicate that IL-29 might exacerbate inflammatory 
reactions in cooperation with other inflammatory mediators, such as proinflammatory 
cytokines or toll-like receptor ligands.  
We found that IL-29 activated various signal transductions pathways, including the MAPK, 
STAT1, Akt, and NF-κB pathways. Some previous studies have examined the signal 
pathways that are activated by IL-29 stimulation. Xu et al. reported that IL-29 induced p38 
MAPK, ERK, JNK, STAT1, and NF-κB p65 phosphorylation in human synovial fibroblasts 
although they also showed that IL-29 did not induce STAT3 or Akt phosphorylation [Xu et al., 
2016]. Guenterberg et al. demonstrated that IL-29 enhanced STAT1 phosphorylation in a 
human melanoma cell line although it did not enhance the basal phosphorylation of STAT3 
[Guenterberg et al., 2010]. Brands et al. reported that IL-29 induced p38 MAPK, ERK, JNK, 
and Akt phosphorylation in human intestinal epithelial cells [Brand et al., 2005]. Judging 
from previous reports and ours, we consider that IL-29 induces p38 MAPK, ERK, JNK, 
STAT1, and NF-κB p65 phosphorylation although STAT3 phosphorylation is not modulated 
by IL-29 stimulation. We suggest that IL-29 might activate the Akt pathway in a cell 
type-dependent manner.  
In this study, we demonstrated that the p38 MAPK, STAT3, and NF-κB pathways positively 
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regulate CXCL10 production in IL-29-stimulated TR146 cells. We previously showed that a 
p38 MAPK inhibitor and a STAT3 inhibitor significantly decreased CXCL10 production in 
oncostatin M-treated human gingival fibroblasts [Hosokawa et al., 2010]. We recently 
reported that the p38 MAPK and NF-κB pathways are involved in CXCL10 production in 
IL-1β-stimulated human periodontal ligament cells [Hosokawa et al., 2016]. Taken together, 
our previous studies and this study demonstrate that the p38 MAPK, STAT3, and NF-κB 
pathways are essential for CXCL10 production. A JNK inhibitor enhanced CXCL10 
production in this study, whereas a JNK inhibitor decreased CXCL10 production in 
IL-1β-stimulated human periodontal ligament cells in our previous studies. We consider that 
the role of JNK in CXCL10 production is dependent on the kind of cell or irritant involved. 
Moreover, we showed that an ERK inhibitor increased CXCL10 production in TR146 cells. 
Zaheer et al. reported that PD98059 enhanced human rhinovirus-induced CXCL10 
production in human airway epithelial cells [Zaheer et al., 2009]. Based on the results of our 
previous and present studies, we suggest that the ERK pathway negatively regulates CXCL10 
production.  
In conclusion, IL-29 enhanced CXCL10 production in human oral epithelial cells via the p38 
MAPK, STAT3, and NF-κB pathways, which might control Th1-cell accumulation in 
periodontal lesions and be involved in pathological processes in periodontal disease.  
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Figure legends 
Fig. 1. IL-10 receptor β and IL-28 receptor α expression in TR146 cells  
The extracts of non-stimulated TR146 cells were subjected to SDS-PAGE. Western blot 
analysis with antibodies against IL-10 receptor β, IL-28 receptor α, and GAPDH was 
performed. 
Fig. 2. The effect of IL-29 on CXCL10 production in TR146 cells 
TR146 cells were incubated with human recombinant IL-29 (1, 10, or 100 ng/ml) for 24 
hours, and then the supernatant was collected. The concentration of CXCL10 in each 
supernatant was measured using ELISA. The results are shown as the mean and SD values of 
a representative experiment performed in triplicate. The error bars represent the SD. * = 
P<0.05, significantly different from the non-stimulated TR146 cells 
Fig. 3. Effect of IL-29 on CXCL10 production in TNF-α-stimulated TR146 cells  
TR146 cells were stimulated with TNF-α (10 ng/ml) with or without IL-29 (1, 10, or 100 
ng/ml). Their supernatants were collected after 24 hours. The concentrations of CXCL10 in 
the supernatants were measured using ELISA. The results are shown as the mean and SD of a 
representative experiment performed in triplicate. The error bars indicate the SD. * = P<0.05, 
significantly different from the TNF-α-stimulated TR146 cells that were not treated with 
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IL-29 
Fig. 4. Effects of signal transduction inhibitors on CXCL10 production in 
IL-29-stimulated TR146 cells 
  TR146 cells were incubated with SB203580 (10 µΜ), PD98059 (10 µΜ), SP600125 (10 
µΜ), fludarabine (50 µΜ), WP1066 (5 µΜ), 10-DEBC hydrochloride (5 µΜ), or SC514 (10 
µΜ) for 1 hour and then stimulated with human recombinant IL-29 (100 ng/ml). Their 
supernatants were collected after 24 hours. The concentrations of CXCL10 in the 
supernatants were measured using ELISA. The results are shown as the mean and SD of a 
representative experiment performed in triplicate. The error bars indicate the SD. * = P<0.05, 
significantly different from the IL-29-stimulated TR146 cells that were not pretreated with 
signal transduction inhibitors 
Fig. 5. p38 MAPK, STAT3, and NF-κB p65 phosphorylation in TR146 cells treated with 
IL-29 with or without TNF-α  
 The cultured cells were treated with IL-29 (100 ng/ml) alone or IL-29 (100 ng/ml) and 
TNF-α (10 ng/ml) for 15, 30, or 60 min. The cells were lysed in lysis buffer containing 
protease inhibitors, and the phosphorylation of p38 MAPK, STAT3, and NF-κB p65 was 
assessed using Western blot analysis. Representative Western blot data that indicates the 
phospho-p38 MAPK, total p38 MAPK, phospho-STAT3, total STAT3, phospho-NF-κB p65, 
total NF-κB p65, and GAPDH levels detected in the TR146 cells during three independent 
experiments are shown. 
 15 
 
References 
1. Arpaci D, Karakas Celik S, Can M, Cakmak Genc G, Kuzu F, Unal M, Bayraktaroglu T: 
2016. Increased Serum Levels of IL-28 and IL-29 and the Protective Effect of IL28B 
rs8099917 Polymorphism in Patients with Hashimoto's Thyroiditis. Immunol Invest. 45: 
668-78. 
 
2. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diebold J, 
Diepolder H, Adler B, Auernhammer CJ, Göke B, Dambacher J: 2005. IL-28A and 
IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and 
murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest 
Liver Physiol. 289: G960-968. 
 
3. Chen XT, Chen LL, Tan JY, Shi DH, Ke T, Lei LH: 2016. Th17 and Th1 
Lymphocytes Are Correlated with Chronic Periodontitis. Immunol Invest. 45: 243-254. 
 
4. Gaffen SL, Hajishengallis G: 2008. A new inflammatory cytokine on the block: 
re-thinking periodontal disease and the Th1/Th2 paradigm in the context of Th17 cells 
and IL-17. J Dent Res. 87: 817-828. 
 
 16 
5. Guenterberg KD, Grignol VP, Raig ET, Zimmerer JM, Chan AN, Blaskovits FM, 
Young GS, Nuovo GJ, Mundy BL, Lesinski GB, Carson WE 3rd: 2010. Interleukin-29 
binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis. Mol 
Cancer Ther. 9: 510-520. 
 
6. Hiroshima Y, Bando M, Inagaki Y, Kido R, Kataoka M, Nagata T, Kido J: 2016. 
Effect of Hangeshashinto on calprotectin expression in human oral epithelial cells. 
Odontology. 104: 152-162.  
 
7. Hosokawa I, Hosokawa Y, Shindo S, Ozaki K, Matsuo T: 2016. Melatonin Inhibits 
CXCL10 and MMP-1 Production in IL-1β-Stimulated Human Periodontal Ligament 
Cells. Inflammation. 39: 1520-1526. 
 
8. Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T: 2009. Cytokines 
differentially regulate CXCL10 production by interferon-gamma-stimulated or tumor 
necrosis factor-alpha-stimulated human gingival fibroblasts. J Periodontal Res. 44: 
225-231.  
 
9. Hosokawa Y, Hosokawa I, Ozaki K, Nakanishi T, Nakae H, Matsuo T: 2010. 
Catechins inhibit CXCL10 production from oncostatin M-stimulated human gingival 
 17 
fibroblasts. J Nutr Biochem. 21: 659-664. 
 
10. Hosokawa Y, Hosokawa I, Shindo S, Ozaki K, Matsuo T: 2015. Calcitriol 
Suppressed Inflammatory Reactions in IL-1β-Stimulated Human Periodontal Ligament 
Cells. Inflammation. 38: 2252-2258. 
11. Jacobsen J, Nielsen EB, Brøndum-Nielsen K, Christensen ME, Olin HB, 
Tommerup N, Rassing MR: 1999. Filter-grown TR146 cells as an in vitro model of 
human buccal epithelial permeability. Eur J Oral Sci. 107:138-146. 
 
11. Kohli A, Islam A, Moyes DL, Murciano C, Shen C, Challacombe SJ, Naglik JR: 
2014. Oral and vaginal epithelial cell lines bind and transfer cell-free infectious HIV-1 
to permissive cells but are not productively infected. Plos One. 9: e98077. 
 
12. Li M, Liu X, Zhou Y, Su SB: 2009. Interferon-lambdas: the modulators of antivirus, 
antitumor, and immune responses. J Leukoc Biol. 86:23-32. 
 
13. Li Y, Gao Q, Yuan X, Zhou M, Peng X, Liu X, Zheng X, Xu D, Li M: 2014. 
Adenovirus expressing IFN-λ1 (IL-29) attenuates allergic airway inflammation and 
airway hyperreactivity in experimental asthma. Int Immunopharmacol. 21: 156-162. 
 
 18 
14. Megjugorac NJ, Gallagher GE, Gallagher G: 2010. IL-4 enhances IFN-lambda1 
(IL-29) production by plasmacytoid DCs via monocyte secretion of IL-1Ra. 
Blood.115: 4185-4190. 
 
15. Melchjorsen J, Sirén J, Julkunen I, Paludan SR, Matikainen S: 2006. Induction of 
cytokine expression by herpes simplex virus in human monocyte-derived macrophages 
and dendritic cells is dependent on virus replication and is counteracted by ICP27 
targeting NF-kappaB and IRF-3. J Gen Virol. 87: 1099-1108. 
 
16. Pekarek V, Srinivas S, Eskdale J, Gallagher G: 2007. Interferon lambda-1 
(IFN-lambda1/IL-29) induces ELR(-) CXC chemokine mRNA in human peripheral 
blood mononuclear cells, in an IFN-gamma-independent manner. Genes Immun. 8: 
177-180. 
 
17. Qian Z, Travanty EA, Oko L, Edeen K, Berglund A, Wang J, Ito Y, Holmes KV, 
Mason RJ: 2013. Innate immune response of human alveolar type II cells infected with 
severe acute respiratory syndrome-coronavirus. Am J Respir Cell Mol Biol. 48: 
742-748. 
 
18. Rajesh N, Arun KV, Kumar TS, Reddy KK, Alamelu S, Reddy BR: 2015. 
 19 
Evaluation of mRNA expression of the transcription factors of Th1 and Th2 subsets 
(T-bet and GATA-3) in periodontal health and disease - A pilot study in south Indian 
population. J Indian Soc Periodontol. 19: 624-627. 
 
19. Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, Hamid Q, 
Luster AD: 1999. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are 
expressed by activated human bronchial epithelial cells. J Immunol. 162: 3549-3558. 
 
20. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, 
Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell 
Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, 
McKnight G, Clegg C, Foster D, Klucher KM: 2003. IL-28, IL-29 and their class II 
cytokine receptor IL-28R. Nat Immunol. 4: 63-68. 
 
21. Shivaprasad BM, Pradeep AR: 2013. Effect of non-surgical periodontal therapy on 
interleukin-29 levels in gingival crevicular fluid of chronic periodontitis and aggressive 
periodontitis patients. Dis Markers. 34: 1-7. 
 
22. Sorenson BS, Khammanivong A, Guenther BD, Ross KF, Herzberg MC: 2012.  
IL-1 receptor regulates S100A8/A9-dependent keratinocyte resistance to bacterial 
 20 
invasion. Mucosal Immunol. 5: 66-75. 
 
23. Souza PP, Lerner UH. 2013. The role of cytokines in inflammatory bone loss. 
Immunol Invest. 42:555-622. 
 
24. Srinivas S, Dai J, Eskdale J, Gallagher GE, Megjugorac NJ, Gallagher G: 2008.  
Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over 
other T helper type 2 cytokine responses in vitro. Immunology. 125: 492-502. 
 
25. Taubman MA, Kawai T: 2001. Involvement of T-lymphocytes in periodontal 
disease and in direct and indirect induction of bone resorption. Crit Rev Oral Biol Med. 
12: 125-135. 
 
26. Witte E, Kokolakis G, Witte K, Warszawska K, Friedrich M, Christou D, Kirsch S, 
Sterry W, Volk HD, Sabat R, Wolk K: 2016. Interleukin-29 induces epithelial 
production of CXCR3A ligands and T-cell infiltration. J Mol Med. 94: 391-400. 
 
27. Witte K, Witte E, Sabat R, Wolk K: 2010. IL-28A, IL-28B, and IL-29: promising 
cytokines with type I interferon-like properties. Cytokine Growth Factor Rev. 21: 
237-251. 
 21 
 
28. Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G, Nasilowska K, Thilo J, Asadullah 
K, Sterry W, Volk HD, Sabat R: 2008. Maturing dendritic cells are an important source of 
IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J 
Leukoc Biol. 83:1181-1193. 
 
29. Wu S, Xue J, Yang Y, Zhu H, Chen F, Wang J, Lou G, Liu Y, Shi Y, Yu Y, Xia C, Hu 
Y, Chen Z: 2015. Isoliquiritigenin Inhibits Interferon-γ-Inducible Genes Expression in 
Hepatocytes through Down-Regulating Activation of JAK1/STAT1, IRF3/MyD88, 
ERK/MAPK, JNK/MAPK and PI3K/Akt Signaling Pathways. Cell Physiol Biochem. 
37: 501-514. 
 
30. Xu D, Yan S, Wang H, Gu B, Sun K, Yang X, Sun B, Wang X: 2015. IL-29 
Enhances LPS/TLR4-Mediated Inflammation in Rheumatoid Arthritis. Cell Physiol 
Biochem. 37: 27-34. 
 
31. Xu L, Feng X, Tan W, Gu W, Guo D, Zhang M, Wang F: 2013. IL-29 enhances 
Toll-like receptor-mediated IL-6 and IL-8 production by the synovial fibroblasts from 
rheumatoid arthritis patients. Arthritis Res Ther. 15: R170. 
 
 22 
32. Xu L, Peng Q, Xuan W, Feng X, Kong X, Zhang M, Tan W, Xue M, Wang F: 2016.  
Interleukin-29 Enhances Synovial Inflammation and Cartilage Degradation in 
Osteoarthritis. Mediators Inflamm. 2016: 9631510. 
 
33. Zaheer RS, Koetzler R, Holden NS, Wiehler S, Proud D: 2009. Selective 
transcriptional down-regulation of human rhinovirus-induced production of CXCL10 
from airway epithelial cells via the MEK1 pathway. J Immunol. 182: 4854-4864. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23 
 
 
 24 
 
 
 25 
 
 
 26 
 
 
 27 
 
